BRAF and neoplasm: Indeed, it has been previously shown that MAPK activation by mutants B-RAF drives melanoma tumor proliferation, and that the resistance to B-RAF inhibitors—responsible for their short-duration response—can be (or not) associated with reactivation of the MAPK pathway (“escape route”) [41–43].